HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Takeda Offloads Emerging Market OTCs to Acino

Executive Summary

Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay down debt and focus its portfolio following its acquisition of Shire. 

You may also be interested in...



EU Business Round-Up: BioGaia Seeks Bigger Slice Of UK, Acino Gets Middle East Backers, Boots Moves Into Advertising

The latest European consumer health business news: BioGaia to distribute full probiotics portfolio in the UK; UAE's ADQ snaps up Switzerland's Acino; and Boots launches a personalized ad offering in the UK.

EU Business Round-Up: Gilbert Grabs Grimberg, Navamedic Adds Brain Health Probiotic, Acino Acquires Russian Portfolio

Latest European consumer health business news: Laboratoires Gilbert strengthens its position in France with Grimberg acquisition; Norway's Navamedic secures distribution of brain health probiotic; and Switzerland's Acino gains two supplements popular in Russia.

Hypera Strikes Takeda Deal To Dominate Brazil's OTC Market

Brazil's Hypera is paying Takeda $0.8bn for a portfolio of brands which will make it the "undisputed leader" in the South American country's OTC market. 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel